氟替卡松
![]() | |
![]() | |
臨床資料 | |
---|---|
AHFS/Drugs.com | Monograph |
懷孕分級 |
|
給藥途徑 | 鼻腔內吸入,局部塗搽 |
ATC碼 | |
法律規範狀態 | |
法律規範 |
|
藥物動力學數據 | |
生物利用度 | 0.51% (鼻腔內) |
血漿蛋白結合率 | 91% |
藥物代謝 | 鼻腔內 肝臟(CYP3A4-中介) |
生物半衰期 | 10小時 |
排泄途徑 | 腎臟 |
識別資訊 | |
| |
CAS號 | 80474-14-2((丙酸酯)) ![]() 90566-53-3 ![]() |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
化學資訊 | |
化學式 | C22H27F3O4S |
摩爾質量 | 444.508 g/mol |
3D模型(JSmol) | |
| |
|
氟替卡松(英語:fluticasone)為一種綜合的糖皮質激素。[1]
與糠酸酯(furoate)或丙酸酯(propanoate)的合成品可以用為局部抗炎性、比如鼻炎方面:[2]
參見
註釋
- ^ Briggs, Gerald G.; Freeman, Roger K.; Yaffe, Sumner J., Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk, Lippincott Williams & Wilkins: 600, 2012 [2013-10-28], ISBN 1451153597, (原始內容存檔於2014-01-01).
- ^ Spratto, George R.; Woods, Adrienne L., Delmar Nurse's Drug Handbook 2012, Cengage Learning: 748, 2012 [2013-10-28], ISBN 1111310653, (原始內容存檔於2014-01-01).
參考文獻
- Jarvis B., Faulds D. (1999): Inhaled fluticasone propionate: A review of its therapeutic efficacy at dosages < or = 500 microg/day in adults and adolescents with mild to moderate asthma. Drugs, 57(5), 769–803. PMID 10353302
- Johnson M. (1995): The anti-inflammatory profile of fluticasone propionate. Allergy, 50(23), 11–14. PMID 7604948
- Keating G.M., McCormack P.L. (2007): Salmeterol/fluticasone propionate: a review of its use in the treatment of chronic obstructive pulmonary disease. Drugs, 67(16), 2383–2405. PMID 17983257
- Reynolds N.A., Lyseng-Williamson K.A., Wiseman L.R. (2005): Inhaled salmeterol/fluticasone propionate: a review of its use in asthma. Drugs, 65(12), 1715–1734. PMID 16060707
- Spencer C.M., Jarvis B. (1999): Salmeterol/fluticasone propionate combination. Drugs, 57(6), 933–940. PMID 10400406
- Staresinic A.G., Sorkness C.A. (2000): Fluticasone propionate: A potent inhaled corticosteroid for the treatment of asthma. Expert Opin Pharmacother, 1(6), 1227-1244. PMID 11249490
- Avamys, Zusammenfasuung der Merkmale des Arzneimittels (PDF; 440 kB), Stand Dezember 2012, Europäische Arzneimittelagentur.
|
|